in vitro News and Research

RSS

The Native Antigen Company introduces ten new SARS-CoV-2 specific antibodies

The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the introduction of ten new monoclonal antibodies recognizing SARS-CoV-2, the causative agent of COVID-19.

8 Oct 2020

Proteolytic cleavage of nucleocapsid helps SARS-CoV-2 evade host immune responses

A team of scientists of the University of Oxford reveals that the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) undergoes autoproteolysis, and that resulting products can escape the host immune responses and facilitate viral proliferation. The study is currently available on the bioRxiv preprint server.

7 Oct 2020

Amniotic fluid stem cells may lead to better treatment for ischemic stroke

A study released today in STEM CELLS Translational Medicine points the way to a possible new avenue of treatment for ischemic stroke.

7 Oct 2020

Optimized low‐dose drug combinations to effectively treat colorectal cancer

Chemotherapy-based cancer treatment has distressing side effects for patients and increases the risk of developing resistance to the treatment.

6 Oct 2020

Study reveals potential utility of artemisinin-based treatments against SARS-CoV-2

In a recent, methodologically robust bioRXiv preprint paper, researchers from Germany, Denmark and Hong Kong report in vitro efficacy of extracts from the sweet wormwood plant (Artemisia annua), but also artemisinin, artesunate and artemether derivatives against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Oct 2020

Production of six monoclonal antibodies against SARS-CoV-2 spike protein

Youjia Guo et al. in a recent bioRxiv preprint paper demonstrate the robust performance of mouse anti-SARS-CoV-2 spike monoclonal antibodies in immunoassays, including western blotting, ELISA, immunofluorescence, and immunoprecipitation and also neutralizing activity in vitro against SARS-CoV-2 infection.

5 Oct 2020

Macrophage subgroups may play pivotal role in COVID-19 lethality

Many researchers are attempting to identify risk factors for severe or critical COVID-19. A recent paper in the journal Medical Hypotheses in September 2020 suggests that macrophage class activation is one of the factors that determine the clinical phenotype of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

5 Oct 2020

Potential drug treatment for AXL-low expressing EGFR-mutated lung cancer

Researchers at Kanazawa University report in Nature Communications the mechanism making some lung-cancer patients resistant to the drug osimertinib.

5 Oct 2020

Midges and mosquitoes unlikely to spread SARS-CoV-2

A recent study published on the preprint server bioRxiv* in September 2020 looked to see if biting insects pose a risk for transmission of SARS-CoV-2 to humans or animals following a SARS-CoV-2 infected blood meal.

5 Oct 2020

Feasibility of using dry reagents LAMP assay for SARS-CoV-2 detection

In a new study published on the preprint server medRxiv, researchers evaluated the suitability of the Loopamp SARS-CoV-2 Detection kit from Eiken Chemica, Japan, for detecting SARS-CoV-2. This is a LAMP method that uses dry reagents for RNA amplification.

5 Oct 2020

Investigation of SARS-CoV-2 antibody responses in patients with aggressive hematological malignancies

Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-cancer therapy. While no obvious correlation is found between the serological results and the hematological diagnosis and the treatment, the immune response is similar to the severity of COVID-19 infection observed in the general population.

4 Oct 2020

Anti-sense agents suppress SARS-CoV-2 virus

Researchers in the United States have conducted a study showing that anti-sense agents called peptide-conjugated morpholino oligomers (PPMOs) have the ability to specifically and potently suppress the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

4 Oct 2020

Researchers detect cancer cells at an early stage of development via luminescent nanothermometers

Rovira i Virgili University's study on luminescent thermometry reveals new insights into cancer detection, leveraging advanced thermal control technologies.

From Linkam Scientific Instruments 2 Oct 2020

PATH wins grant to develop oral treatment option for soil-transmitted helminth infections

PATH announced today they received a grant from Japan's Global Health Innovative Technology Fund to develop a new oral treatment option for soil-transmitted helminth infections.

1 Oct 2020

Combinational therapy with antibiotics and stem cells effectively treats bone infections

Bone infections caused by implants are difficult to treat and usually require a prolonged course of antibiotic treatment.

1 Oct 2020

Planaria flatworm can be used as reliable alternative for testing topical skin products

Tests for skin treatments could be screened using flatworms rather than other animals such as rabbits, according to new research.

1 Oct 2020

Researchers identify a potential target for small cell lung cancer

The cover for issue 39 of Oncotarget features Figure 4, "Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves," by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1.

1 Oct 2020

New device for monitoring coronary artery disease in real-time

Coronary artery disease - a leading cause of death in the US - narrows or blocks arteries that carry a vital supply of blood, oxygen, and nutrients to the heart.

30 Sep 2020

Newly developed fusion protein could improve COVID-19 research

Researchers at the Paul Scherrer Institute in Switzerland have developed a high-quality recombinant virus protein that could be applied in the development of vaccines against the 2019 novel coronavirus (2019-nCoV) and in the detection of novel viruses or antibodies.

30 Sep 2020

Exosomes yield regenerative benefits equivalent to hiPSC-CCs, shows study

Science has long known that recovery from experimental heart attacks is improved by injection of a mixture of heart muscle cells, endothelial cells and smooth muscle cells, yet results have been limited by poor engraftment and retention, and researchers worry about potential tumorigenesis and heart arrhythmia.

30 Sep 2020